trending Market Intelligence /marketintelligence/en/news-insights/trending/KJaXzXkj6oKIIVuT7Xn6Sw2 content esgSubNav
In This List

Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

Axsome Therapeutics Inc. raised about $23.3 million from a stock offering carried out with Leerink Partners LLC.

The New York-based biopharmaceutical company sold 2,881,066 shares in the offering.

Axsome intends to use the proceeds to fund the ongoing clinical development of its late-stage product candidates and for other general corporate purposes.

Just recently, the company, which develops therapies for managing central nervous system disorders, reported positive data from a mid-stage study, which showed that its medicine AXS-05 helped reduce depression symptoms in patients.